VRTX vs WAT
Vertex Pharmaceuticals vs Waters Corporation — AI-powered side-by-side comparison
VRTX
Vertex Pharmaceuticals
67
Buy
VS
WAT
Waters Corporation
70
Buy
| Metric | VRTX | WAT |
|---|
| AI Score |
67
|
70
|
| Price |
$496.21
|
$406.91
|
| P/E Ratio |
28.64×
|
101.21×
|
| ROE |
21.2%
|
25.1%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
86.0%
|
50.8%
|
| Debt / Equity |
0.00×
|
0.33×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
66.6
|
75.0
|
| Beta |
0.292
|
1.202
|
| Expected Upside |
+2.3%
|
+0.2%
|
AI Committee View
Current Innellis committee reasoning for VRTX versus WAT.
WAT leads by 3 points.
WAT scores 70/100 (Buy) versus VRTX at 67/100 (Buy).
VRTX Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock. The main limiting factor is p/e of 28.3 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 23.3% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 28.3 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- Price trading above the upper Bollinger Band -- stretched — Technical
WAT Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is rsi at 75 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 75 is in overbought territory — Technical
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical